Technology | CT Angiography (CTA) | June 16, 2017

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Visipaque is the first FDA-approved contrast agent indicated for non-invasive CCTA procedure 

GE Healthcares imaging agent Visipaque, iodixanol, is now cleared for use with cardiac CT angiography, CCTA

June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s imaging agent Visipaque (iodixanol) Injection. Visipaque 320 mg iodine/mL is an iso-osmolar agent that is now approved for use in coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of adult and pediatric patients 12 years of age or older with suspected coronary artery disease in the United States.

The new CCTA indication allows healthcare practitioners to image the coronary arteries of patients with suspected coronary artery disease (CAD), offering a non-invasive approach to diagnosis. Traditionally, radiologists and cardiologists have utilized invasive coronary angiography (ICA) procedures to diagnose potential CAD in patients, which can be costly and result in longer patient hospital stays. With Visipaque’s CCTA label extension, healthcare practitioners now have an FDA-approved contrast agent in CCTA procedures that can be performed as an outpatient procedure when evaluating patients with suspected CAD.
 
“Coronary heart disease is a major cause of death in the United States,” said Matt Budoff, M.D., FACC, director of cardiac CT and professor of medicine, Harbor-UCLA Medical Center, Torrance, Calif. “We are excited about the label extension of Visipaque as the first FDA approved iodinated contrast media for use in CCTA. Having an approved contrast agent for CCTA may facilitate the use of CCTA as a gatekeeper to ICA in patients with mild to moderate coronary artery disease, sparing patients from a more invasive procedure and long recovery times.”

Label extension approval for Visipaque 320 mg Iodine/mL for CCTA was evaluated in two prospective, multicenter clinical studies in a total of 1,106 adult patients. Data from the two studies showed that Visipaque has a 99 percent negative predictive value in the diagnosis of CAD (study 1: sensitivity (76-89 percent), specificity (84-89 percent); study 2: sensitivity (95 percent), specificity (87 percent))[1]. Visipaque’s label extension further enhances GE Healthcare’s cardiology portfolio, joining, Myoview, Adreview, and the recently announced distribution rights for Rapiscan outside the U.S. and Canada.

For more information: www3.gehealthcare.com/en/products/categories/contrast_media/visipaque

Related Content

New ESC Guideline Provides Class 1 Recommendation for Coronary CTA
News | CT Angiography (CTA) | September 17, 2019
The European Society of Cardiology (ESC) published new ...
HeartFlow Announces FDA Clearance for HeartFlow Planner
Technology | CT Angiography (CTA) | September 12, 2019
HeartFlow Inc. has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non...
Videos | CT Angiography (CTA) | August 08, 2019
This is a quick video example of a cardiac computed tomography (CT) exam showing a Medtronic CoreValve transcatheter
Videos | CT Angiography (CTA) | August 08, 2019
This is an example of an automated calcium scoring software to speed review of coronary artery calcium (CAC) scoring
Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. #SCCT19

Siemens Go.Top cardiovascular edition CT scanner with its detachable tablets used by the tech to control the scanner so they can stay at the patient's side longer. (Photo by Dave Fornell)

Feature | CT Angiography (CTA) | August 06, 2019 | Dave Fornell, Editor
There were several interesting new trends in cardiovascular computed tomography (CT) imaging at the 2019...
Artificial Intelligence Improves Heart Attack Risk Assessment
News | CT Angiography (CTA) | August 06, 2019
When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than...
An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting.

An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting. 

Feature | CT Angiography (CTA) | July 24, 2019 | Greg Freiherr
One of the big trends in cardiac computed tomography (CT) imaging has been the introduction of noninvasive ...
Overlay Init